ライフサイエンスコーパス: implantable

1 Here, we show that implantable active coil-based transducers that are detec

2 l coated balloons (PCBs) are a promising non-implantable alternative to drug-eluting stents, whereby

3 of life but the long-term operation of these implantable and wearable devices remains a huge challeng

4 ristics pave the way for new applications in implantable and wearable electronics.

5 in energy and healthcare, such as wearable, implantable, and large-area electronic devices.

6 The simple implantable apparatus enables visualization of live proc

7 le medical devices is to develop mechatronic implantable artificial organs such as artificial pancrea

8 Wearable and implantable bio-integrated electronics have started to g

9 Besides medical applications, implantable bioelectronic brain-computer interfaces are

10 er presents a comprehensive review of recent implantable bioelectronic devices that employ alternativ

11 ning considerable attention as materials for implantable bioelectronics due to their unique features

12 e key challenge for the broad application of implantable biofuel cells (BFCs) is to achieve inorganic

13 issue-engineering, anti-fouling coating, and implantable biomaterials and sensors.

14 trate the first step towards next-generation implantable biomaterials with prolonged release and exce

15 ssential for the development of wearable and implantable biomedical devices.

16 and selectivity of these rapidly prototyped implantable biosensors that can be inserted into a spina

17 The method includes a custom implantable bipolar stimulation and recording lead and f

18 rial among patients with advanced HF with an implantable cardiac defibrillator at high risk of death.

19 sudden cardiac arrests (arrhythmic death or implantable cardiac defibrillator discharge for ventricu

20 ation, nonsustained ventricular tachycardia, implantable cardiac defibrillator discharge, and sudden

21 cause of cardiomyopathy, presence/absence of implantable cardiac defibrillator or cardiac resynchroni

22 symptomatic Brugada syndrome patients having implantable cardiac defibrillator were enrolled: 63 (gro

23 By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+B

24 RB+BB+mineralocorticoid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+B

25 +BB+mineralocorticoid receptor antagonist to implantable cardiac defibrillator+optimal pharmacologica

26 ed for revascularisation, implantation of an implantable cardiac defibrillator, and mitral or tricusp

27 h severe secondary mitral regurgitation, and implantable cardiac defibrillators in patients with more

28 beta-blockers (BBs) alone or in addition to implantable cardiac defibrillators or cardiac resynchron

29 Resterilization and reuse of implantable cardiac devices obtained post mortem from pa

30 detection through smartphone applications or implantable cardiac devices, together with the optimal m

31 TEMI), a multicenter, randomized trial of an implantable cardiac monitor that alerts patients with ra

32 s study, we sought to evaluate the impact of implantable cardiac monitoring (ICM) in the prevention o

33 All the patients received an implantable cardiac monitoring device to detect atrial t

34 ime) from baseline to 12 months, measured by implantable cardiac monitors.

35 Implantable cardiac pacing and defibrillation devices ar

36 Implantable cardiac sensors have shown promise in reduci

37 The implantable cardiac system detects early ST-segment devi

38 evascularizations (n = 5, 17.2%), and urgent implantable cardio-defibrillator/permanent pacemaker pla

39 rgency coronary revascularization, or urgent implantable cardio-defibrillators/permanent pacemaker pl

40 iscussed before and after implantation of an implantable cardioverter defibrillator (ICD) and include

41 Patients with an implantable cardioverter defibrillator (ICD) had tachyca

42 valuate the survival benefit of prophylactic implantable cardioverter defibrillator (ICD) implantatio

43 Data evaluating the implantable cardioverter defibrillator (ICD) in this pat

44 To our knowledge, whether implantable cardioverter defibrillator (ICD) therapy imp

45 and heterogeneity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in

46 ds ratio [OR], 1.21 [95% CI, 1.17-1.25]), no implantable cardioverter defibrillator (OR, 1.46 [95% CI

47 dences of adverse events, drug continuation, implantable cardioverter defibrillator and cardiac resyn

48 patients with LVEF <=35%, who are potential implantable cardioverter defibrillator candidates, treat

49 h higher frequency of palpitation (P=0.004), implantable cardioverter defibrillator implantation (P=0

50 ce guidelines and shared decision making for implantable cardioverter defibrillator insertion.

51 vice-related complications and inappropriate implantable cardioverter defibrillator interventions.

52 Implantable cardioverter defibrillator is the only prove

53 Reduction was observed for both implantable cardioverter defibrillator shocks and antita

54 ecurrences of VT were defined as appropriate implantable cardioverter defibrillator therapies or on t

55 leads, and dependence on a pacemaker with an implantable cardioverter defibrillator without asynchron

56 tening arrhythmia, implantation of pacemaker/implantable cardioverter defibrillator, acute myocardial

57 tients with AF with LVEF <=35% without prior implantable cardioverter defibrillator, cardiac resynchr

58 s defined as (1) sudden cardiac death or (2) implantable cardioverter defibrillator-treated or hemody

59 F, obviating the need for primary prevention implantable cardioverter defibrillator.

60 ch to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a

61 ergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experienc

62 regarding efficacy/clinical effectiveness of implantable cardioverter defibrillators and understand w

63 eatening arrhythmias, as well as the role of implantable cardioverter defibrillators for primary prev

64 THODS AND Pigs implanted with single-chamber implantable cardioverter defibrillators to record ventri

65 uction in VT episodes (tracked by indwelling implantable cardioverter defibrillators) or any reductio

66 herapy summarizes the existing literature on implantable cardioverter defibrillators, biventricular p

67 tly facilitated the choice of candidates for implantable cardioverter defibrillators.

68 propriate shock following primary prevention implantable cardioverter defibrillators.

69 ut noninducible clinical VTs based on stored implantable cardioverter-defibrillator (ICD) electrogram

70 Background Patients undergoing implantable cardioverter-defibrillator (ICD) implantatio

71 entify those patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantatio

72 The feasibility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantatio

73 Penetration of the implantable cardioverter-defibrillator (ICD) into this p

74 The implantable cardioverter-defibrillator (ICD) is effectiv

75 The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and

76 ng the National Cardiovascular Data Registry implantable cardioverter-defibrillator (ICD) registry da

77 tion Registry, and the Swedish Pacemaker and Implantable Cardioverter-Defibrillator (ICD) Registry.

78 (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in s

79 .5 tesla for patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "n

80 Of the 118 ES patients, 21 had appropriate implantable cardioverter-defibrillator (ICD) therapy ter

81 failure (HF) to amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy.

82 Most randomized trials on implantable cardioverter-defibrillator (ICD) use for pri

83 The subcutaneous implantable cardioverter-defibrillator (ICD) was designe

84 In patients with an implantable cardioverter-defibrillator (ICD), shocks are

85 tion ECGs would predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible ca

86 rial arrhythmias are common in patients with implantable cardioverter-defibrillator (ICD).

87 The subcutaneous implantable cardioverter-defibrillator (S-ICD) was devel

88 We excluded patients with prior implantable cardioverter-defibrillator and those randomi

89 among patients receiving primary prevention implantable cardioverter-defibrillator and widening QRS.

90 Although an implantable cardioverter-defibrillator can save lives in

91 (An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conv

92 files correlated with VA events (appropriate implantable cardioverter-defibrillator firings and arrhy

93 In the subcutaneous implantable cardioverter-defibrillator IDE study (Invest

94 e assessed the Guideline recommendations for implantable cardioverter-defibrillator implantation in p

95 may be a predictor of survival benefit after implantable cardioverter-defibrillator implantation in p

96 The most recent recommendations for implantable cardioverter-defibrillator implantation in t

97 een HF quartiles (P=0.91), and the effect of implantable cardioverter-defibrillator implantation on a

98 llation efficacy at the time of subcutaneous implantable cardioverter-defibrillator implantation with

99 Of 314 patients who underwent subcutaneous implantable cardioverter-defibrillator implantation, 282

100 utations is crucial to select candidates for implantable cardioverter-defibrillator implantation.

101 duration of HF, mode of death, and effect of implantable cardioverter-defibrillator implantation.

102 ith the use of a registry containing data on implantable cardioverter-defibrillator implantations fro

103 We conducted the ICD2 trial (Implantable Cardioverter-Defibrillator in Dialysis Patie

104 ndpoint of sudden cardiac death, appropriate implantable cardioverter-defibrillator intervention, and

105 A total of 80 VF events were recorded in the implantable cardioverter-defibrillator logs the 6 months

106 required cardioversion in 2 patients and new implantable cardioverter-defibrillator placement in 2.

107 Subcutaneous implantable cardioverter-defibrillator shock efficacy is

108 point of sudden cardiac death or appropriate implantable cardioverter-defibrillator shock.

109 SCD, aborted cardiac arrest, and appropriate implantable cardioverter-defibrillator shocks) was 0.84

110 I(2)=0%; high-quality evidence), appropriate implantable cardioverter-defibrillator therapy (5 studie

111 predicts long-term mortality and appropriate implantable cardioverter-defibrillator therapy in ischem

112 his disease, it is also well recognized that implantable cardioverter-defibrillator therapy is associ

113 ac events (sudden cardiac death, appropriate implantable cardioverter-defibrillator therapy, resuscit

114 tients who may not benefit from prophylactic implantable cardioverter-defibrillator therapy.

115 ined VA (>=30s, hemodynamically unstable, or implantable cardioverter-defibrillator treated ventricul

116 s with LTVA (SCD, aborted SCD, sustained, or implantable cardioverter-defibrillator treated ventricul

117 ac magnetic resonance assessment may improve implantable cardioverter-defibrillator treatment decisio

118 o, 1.50 [CI, 1.13-1.99], P<0.01) but neither implantable cardioverter-defibrillator utilization nor v

119 Implantation of an implantable cardioverter-defibrillator was considered bu

120 ith longer duration of HF, and the effect of implantable cardioverter-defibrillator was not modified

121 device (cardiac resynchronization therapy or implantable cardioverter-defibrillator).

122 that in LBBB patients, CRT-D, compared with implantable cardioverter-defibrillator, was associated w

123 The CRT-D versus implantable cardioverter-defibrillator-only risk for fir

124 went a septal myectomy; 14 (25%) received an implantable cardioverter-defibrillator; 1 underwent card

125 Background Implantable cardioverter-defibrillators (ICDs) are indic

126 Although implantable cardioverter-defibrillators (ICDs) reduce su

127 te therapy varies widely among recipients of implantable cardioverter-defibrillators (ICDs).

128 educes the recurrence of VT in patients with implantable cardioverter-defibrillators (ICDs).

129 optimizing treatment for patients receiving implantable cardioverter-defibrillators (ICDs).

130 , beta-blockers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%)

131 Implantable cardioverter-defibrillators are used to prev

132 retrospective cohort study of patients with implantable cardioverter-defibrillators identified from

133 Cardiac resynchronization therapy and implantable cardioverter-defibrillators may be required

134 rdiac arrests and lives potentially saved by implantable cardioverter-defibrillators, all de novo imp

135 Pharmacotherapy, implantable cardioverter-defibrillators, and left cardia

136 prognosticator and guide the optimal use of implantable cardioverter-defibrillators.

137 al outcomes in patients with advanced HF and implantable cardioverter-defibrillators.

138 dysrhythmia by cardiac resynchronisation and implantable cardioverter-defibrillators; neurohumoral mo

139 We have developed a clinically validated, implantable cell encapsulation system that delivers high

140 igh risk for stroke with a previously placed implantable CIED, but without a prior diagnosis of clini

141 serve as a middle-ear microphone for totally implantable cochlear- or middle-ear hearing aids.

142 e the postoperative visual outcomes of toric implantable collamer lens (T-ICL) with toric Artiflex (T

143 at are vascularized, autologous, functional, implantable, cost-effective, and ethically feasible.

144 he Percept PC, the first FDA-approved, fully-implantable DBS device capable of nearly-simultaneous el

145 treatment, there is a clear need for a fully-implantable DBS system capable of chronically recording

146 Need for implantable defibrillator (LVEF <=30%) was reduced in th

147 Thirteen (68%) patients have received implantable defibrillators.

148 Procedure-related cardiac electronic implantable device (CIED) infections have high morbidity

149 Here, we present a microscale implantable device - the nanoclip - for chronic interfac

150 ce topographies to probe the interactions of implantable device coatings with cells and tissues.

151 Patients from the multicenter Study of an Implantable Device for Lowering Intraocular Pressure in

152 Patients from the multicenter Study of an Implantable Device for Lowering Intraocular Pressure in

153 A fully implantable device, however, would ultimately be desirab

154 d validate interventions such as wearable or implantable device-based monitoring ultimately to interv

155 agnetic (EM) fields amongst the wearable and implantable devices act as the backbone for information

156 more relaxed regulatory framework governing implantable devices and interventions compared with that

157 Thus, implantable devices and long-acting parenteral prodrugs

158 ric materials and structures in wearable and implantable devices are briefly summarized.

159 s and clinical applications of bioresorbable implantable devices are reviewed.

160 open possibilities for the new generation of implantable devices for healthcare monitoring.

161 discussed, followed by their applications as implantable devices in biomedical engineering.

162 ound closure, hemostasis, and integration of implantable devices onto wet tissues.

163 Implantable devices partially overcome these issues but

164 However, the scaling down of implantable devices raises the problem of how to power t

165 Current commercially available implantable devices that allow for recording and stimula

166 es in fabrication and biomaterials to create implantable devices that generate bone within the patien

167 leen circuit, which has been stimulated with implantable devices to improve autoimmune conditions suc

168 ve and sealant, and in adhering wearable and implantable devices to wet tissues.

169 Current cochlear implants (CIs) are semi-implantable devices with an externally worn sound proces

170 In electrophysiology, implantable devices with CP coating or CP-only electrode

171 agnostic modalities, wearable biosensors and implantable devices, which electrical components are of

172 n, has the potential to replace batteries in implantable devices.

173 have been commercially used for fabricating implantable devices.

174 lectrodes, tunable phononic crystals and bio-implantable devices.

175 nthetic polymers) used in the fabrication of implantable devices.

176 ring, diagnostics, therapy, and wearable and implantable devices.

177 are attractive for flexible electronics and implantable devices.

178 s (IE) in patients with prosthetic valves or implantable devices.

179 sive drug-release system that may be used in implantable devices.

180 lly focus on amplification using wearable or implantable devices; however exciting new gene-therapy-b

181 A closed-loop implantable drug delivery system is an ideal solution to

182 o-fabricated smart drug delivery systems and implantable drug loaded biomaterials for brain repair ar

183 The implantable drug-delivery system can be powered with a T

184 tric-nanogenerator (TENG)-based self-powered implantable drug-delivery system is presented.

185 icant step forward toward the development of implantable drug-delivery systems.

186 In the present study, an implantable dual delivery platform was developed using c

187 s paper, we report an ultrasonically powered implantable EA microprobe that may increase the clinical

188 ity of being constituted by a biocompatible, implantable, edible commodity textile material.

189 , valvular heart disease, and cardiovascular implantable electrical devices.

190 The upper bound of the 'Implantable electrical probes' box also incorrectly show

191 e have been increasing efforts in developing implantable electrode arrays capable of housing cultured

192 -directed medical therapy and with a cardiac implantable electronic device (cardiac resynchronization

193 rrent understanding of the impact of cardiac implantable electronic device (CIED) infection is based

194 procedural interventions and cardiovascular implantable electronic device and cardiac resynchronizat

195 s common practice to maintain cardiovascular implantable electronic device detection and therapies af

196 The presence of a cardiovascular implantable electronic device has long been a contraindi

197 Cardiac implantable electronic device infection is a major compl

198 resulted in a 40% reduction of major cardiac implantable electronic device infection without increase

199 system by reducing the incidence of cardiac implantable electronic device infection.

200 t in cases of prosthetic valve IE or cardiac implantable electronic device infection.

201 dministration serviced patients with cardiac implantable electronic device remote monitoring data and

202 y 4 of them were managed with cardiovascular-implantable electronic device removal and reimplantation

203 lication in 6983 patients undergoing cardiac implantable electronic device revision, replacement, upg

204 icuspid valve procedure, or a cardiovascular implantable electronic device that would inhibit TriClip

205 led trials involving medications and cardiac implantable electronic device therapies.

206 infection risk score in the largest cardiac implantable electronic device trial to date, warranting

207 nanticoagulated patients with cardiovascular implantable electronic devices (age, 68.6+/-12.7 years;

208 The use of cardiac implantable electronic devices (CIED) is increasing, and

209 Cardiovascular implantable electronic devices (CIEDs) are associated wi

210 Infections after placement of cardiac implantable electronic devices (CIEDs) are associated wi

211 Cardiac implantable electronic devices (CIEDs) chronic infection

212 Cardiac implantable electronic devices (CIEDs) have been among t

213 g and sonication of explanted cardiovascular implantable electronic devices (CIEDs), is a higher-yiel

214 We included patients with cardiac implantable electronic devices and remote monitoring fro

215 ent an update on self-powered cardiovascular implantable electronic devices and wearable active senso

216 The widespread use of cardiac implantable electronic devices and wearable monitors has

217 bolism (SSE) in patients with cardiovascular implantable electronic devices as a function of both CHA

218 edtronic CareLink database of cardiovascular implantable electronic devices capable of continuous AF

219 response in patients with HFrEF with cardiac implantable electronic devices favorably influences exer

220 scenarios of prosthetic valve IE and cardiac implantable electronic devices IE, with improving perfor

221 e valve IE, prosthetic valve IE, and cardiac implantable electronic devices IE.

222 alve IE than prosthetic valve IE and cardiac implantable electronic devices IE.

223 ity 0.84 (0.79-0.88, 75.2%); and for cardiac implantable electronic devices IE: sensitivity 0.72 (0.6

224 This review will discuss the use of cardiac implantable electronic devices in heart failure with pri

225 ing the rate-response programming of cardiac implantable electronic devices in patients with HFrEF on

226 hetic valve endocarditis, as well as cardiac implantable electronic devices including pacing devices

227 Cardiovascular implantable electronic devices measure impedance to asse

228 ese patients have preexisting cardiovascular implantable electronic devices or cardiac resynchronizat

229 Studies of patients with cardiovascular implantable electronic devices show a relationship betwe

230 Consequently, energy sources for implantable electronic devices that do not rely on, or a

231 Among 10 212 patients with cardiac implantable electronic devices, 4570 (45%), 3969 (39%),

232 tic valve IE, infections relating to cardiac implantable electronic devices, and indwelling catheters

233 Among veterans with cardiac implantable electronic devices, device-detected AF is co

234 ntinuous remote monitoring data from cardiac implantable electronic devices, we sought to evaluate if

235 valvular extension of infection, and cardiac implantable electronic devices.

236 LV function in people with HFrEF and cardiac implantable electronic devices.

237 he main obstacle in realization of a totally implantable hearing aid is a lack of reliable implantabl

238 serve as a sound source microphone for fully implantable hearing technology such as CIs.

239 "Next-generation" implantable hemodynamic monitors are in development, and

240 These data demonstrate that general use of implantable hemodynamic technology in a nontrial setting

241 d performance of the second generation of an implantable intraocular pressure (IOP) sensor in patient

242 the development of high-performance wearable/implantable ion sensors.

243 k opens a new pathway for the development of implantable light sources that enable functional imaging

244 studies characterizing VLR have not used an implantable loop recorder for ECG monitoring.

245 oballoon pulmonary vein isolation and had an implantable loop recorder implanted <3 months post-ablat

246 without history of AF, undergoing long-term implantable loop recorder monitoring as part of the LOOP

247 Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk

248 Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk

249 lloon pulmonary vein isolation alone, had an implantable loop recorder, and were confirmed AF free fo

250 eral population to undergo screening with an implantable loop recorder.

251 lated screening strategies compared with the implantable loop recorder.

252 All patients received an implantable loop recorder.

253 l strategies had low yield compared with the implantable loop recorder.

254 Our data using implantable loop recorders for continuous ECG monitoring

255 s status, diabetes mellitus, and presence of implantable medical device was studied to gain insights

256 Implantable medical devices have been used for real-time

257 oal for those engaged in research to develop implantable medical devices is to develop mechatronic im

258 Implantable triboelectric nanogenerators for implantable medical devices offer advantages of excellen

259 In particular, replacing batteries in implantable medical devices with electrical harvesting i

260 Self-powered implantable medical electronic devices that harvest biom

261 We demonstrate in particular an implantable metallic glass-based fibre probe tested in v

262 g the mechanical mismatch between tissue and implantable microelectronics is essential for reducing i

263 aper, we introduce an ultrasonically powered implantable microlight source, muLight, which enables in

264 Specifically, subdermal implantable microphone technology has been poised with p

265 mplantable hearing aid is a lack of reliable implantable microphone.

266 Thus, implantable MNs provide a practical means to substantial

267 Clinically available wired implantable monitoring technology requires careful fixat

268 In this study, we develop an implantable multisite optogenetic stimulation device (MO

269 Slow-release, long-acting, implantable naltrexone might improve these outcomes.

270 Here we developed a subcutaneously implantable nanofluidic device for the sustained deliver

271 es are recognized for their miniaturized and implantable nature that can benefit the study of intrace

272 scribe a wireless, leadless and battery-free implantable neural stimulator that is 1.7 mm(3) and that

273 habilitation and motor assistance, including implantable ones.

274 evelopment and application of a micro-needle implantable platinum-based electrochemical sensor for me

275 ensors may have applications in wearable and implantable point-of-care and intensive-care continuous

276 dy of several prototype 3D architectures for implantable probe-array modules that are designed to pro

277 Ambulatory hemodynamic monitoring with an implantable pulmonary artery (PA) sensor is approved for

278 ing at the electrode tips, induced currents, implantable pulse generator dysfunction, and mechanical

279 ps were lead migration (nine [7%] patients), implantable pulse generator pocket pain (five [4%]), and

280 require special considerations which current implantable pulse generators are not designed for.

281 e present results for a novel biocompatible, implantable, scalable, and wirelessly controlled perista

282 ource indicated the probability of realizing implantable self-powered autonomously operated artificia

283 ration implant materials such as pacemakers, implantable sensors, or prosthetic devices in hybrids of

284 thods rely on external imaging techniques or implantable sensors, without the ability to provide cont

285 e we report the design and fabrication of an implantable silicon-based probe that can switch and rout

286 we realized in a 0.18 mum CMOS technology an implantable single-shaft probe with a regular array of 5

287 However, the design of implantable soft electronics (on the order of 10 kPa in

288 Implantable spinal-cord-neuroprostheses aiming to restor

289 While laser ablation and implantable stimulation devices have lowered the morbidi

290 clusion Neutropenia in adults at the time of implantable subcutaneous chest port placement was associ

291 eless, battery-free photometer that is fully implantable subdermally to allow for the interrogation o

292 ch is constrained by the power budget of the implantable system.

293 results are discussed for the development of implantable thermosensitive gels for the controlled rele

294 ction and assembly of functional tissues and implantable tissue grafts.

295 The open circuit voltage of an implantable triboelectric nanogenerator reaches up to 65

296 ly implanted symbiotic pacemaker based on an implantable triboelectric nanogenerator, which achieves

297 Implantable triboelectric nanogenerators for implantable

298 roscale geometry of neural probes, design of implantable ultra-low-power electronics, implementation

299 The implantation strategy for totally implantable venous access ports with the optimal benefit

300 without external stimuli, here, we report an implantable wireless optogenetic device that bypasses th

301 cond during the experiment using a validated implantable wireless telemetry system; high-definition v